Key Information
Chief Investigator: Professor Shahid Khan and Dr Simon Rushbrook
ICTU collaboration: Operations; Database
Email: asp-psc@imperial.ac.uk
Study website : Clinical trials
Trial registration: Pending
Status: Set-up
Asp-PSC: Effect of Aspirin on Reducing Cancer & Mortality in Primary Sclerosing Cholangitis
This study is a multicentre, double-blind, randomised placebo-controlled trial including patients with Primary Sclerosing Cholangitis who have a concurrent diagnosis of inflammatory bowel disease (IBD) and are at least 12 months post diagnosis. 968 patients will be randomised 2:1 Aspirin vs Placebo. Accrual will be over five years, with a minimum participant follow up of five years.
Patients will be seen at screening/baseline, month one and then six monthly (five months after month one, six monthly thereafter) in alignment with routine clinical care.
Therapeutic areas contacts
For contact details please visit Therapeutic areas contacts